Eli Lilly's stock boomed April 17 after announcing a new experimental pill that caused nearly 8% weight loss at certain dosages and lowered blood sugar in patients during a clinical trial.

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

needle-free alternative in the booming weight loss and diabetes market. Eli Lilly on Thursday said its daily obesity pill met the company's goals in the first of several late-stage trials ...

Pharmaceutical company Eli Lilly’s study of its tablet, orforglipron, has raised hopes of an effective and easy-to-use treatment reaching a market dominated by injections.

Eli Lilly & Co.’s stock soared ... reported positive results from a late-stage trial of a GLP-1 treatment for Type 2 diabetes and obesity in pill form. The last time the stock rose as much ...

Eli Lilly shares jumped 15% after a clinical trial of its experimental pill showed it helped ... of orforglipron in promoting weight loss and controlling diabetes has been met with enthusiasm.

Eli Lilly also said patients saw no plateau in their weight loss by the time the study ... There are seven late-stage studies on the pill, including five diabetes trials and two obesity studies.